Study drug OC-1 for CD1a-positive T-ALL or T-LL after relapse
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial tests the safety and early signs of benefit of OC-1 in people with relapsed or hard-to-treat T-cell leukemia/lymphoma (T-ALL/LL) that has a CD1a marker. You may be considered if standard treatments didn’t work or the cancer returned, and if your organs and infections are controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult or a child older than 2 years
- Your cancer cells must be CD1a-positive (at least 20%) by test on blood/cells or tissue
- Your T-ALL/LL must be relapsed or not responding to treatment, even after standard chemotherapy and/or transplant
- Your heart, lungs, liver, kidneys, and brain/nerve function must be good enough for study treatment
- You cannot have an uncontrolled active infection, and you must not have HIV or active hepatitis B or C
- You must not be pregnant or breastfeeding, and (if you can have children) you must use reliable birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR T-cell therapy (obecabtagene autoleucel) given as a consolidation treatment after initial remission to prevent relapse in people with high-risk B-cell ALL. It's for patients who have achieved first remission but still have high-risk features in their leukemia.
This trial tests an experimental CAR-T cell therapy for acute myeloid leukemia (AML) that has returned or not responded to standard treatments. It uses a special marker on leukemia cells (CLL-1) to target and kill them.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
This trial tests a new type of immune therapy—called CD5-targeting CAR T-cells—for people with a hard-to-treat form of T-cell acute lymphoblastic leukemia. It aims to see if these specially designed cells can find and destroy leukemia cells with the CD5 marker.
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
This Phase 1/2 study tests a type of immune therapy (CAR-T cells) made to recognize CD19 and CD22, two markers on B-ALL cells. It is for children and adults with B-ALL that has come back or did not respond to standard treatments, aiming to improve outcomes when other options have failed.
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.